Therapeutical antibodies

• ofatumumab
  5 January 2017

  WKP
  Ofatumumab (trade name Arzerra, also known as HuMax-CD20) is a fully human monoclonal antibody (for the CD20 protein) which appears to inhibit early-stage B lymphocyte activation.
  It is FDA approved for treating chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab (Campath) and has also shown potential in treating Follicular non-Hodgkin’s lymphoma,
  Diffuse large B cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis. Ofatumumab has (...)

• ocrelizumab
  5 January 2017

  WKP
  Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes, and hence is an immunosuppressive drug candidate.
  Trials
  It is under development as a treatment for multiple sclerosis by Hoffmann–La Roche’s subsidiary Genentech.
  It reached Phase III clinical trials for rheumatoid arthritis and lupus erythematosus and Phase II for multiple sclerosis (MS) and hematological cancer.
  In March 2010, Roche announced the suspension of clinical trials in (...)

• tremelimumab
  31 October 2016

  (formerly ticilimumab, CP-675,206) WKP
  Definition: Tremelimumab is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker.
  Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, there is also an inhibitory mechanism (immune checkpoint) that interrupts this destruction. Tremelimumab turns off this inhibitory mechanism and allows CTLs to continue to destroy the cancer cells. This is immune checkpoint blockade.
  Tremelimumab binds (...)

• durvalumab
  9 June 2016

  Imfinzi WP
  Durvalumab is one of PD-L1 inhibitors . It ismonoclonal antibody being investigated for the treatment of cancer. It targets programmed death ligand-1 (PD-L1), developed by MedImmune.
  Clinical trials
  non-small cell lung cancer (NSCLC) - trial combining durvalumab and gefitinib in NSCLC
  advanced metastatic urothelial bladder
  See also
  PD-L1 inhibitors
  immune (...)

• anti-CTLA4
  9 June 2016

  anti-CTLA-4s ; anti-CTLA4
  anti-CTLA4s tremelimumab ipilimumumab
  See also
  immunotherapy immune checkpoint inhibitors

• vedolizumab
  1 June 2016

  Entyvio WP
  Vedolizumab binds to integrin α4β7 (LPAM-1, lymphocyte Peyer’s patch adhesion molecule 1). Blocking the α4β7 integrin results in gut-selective anti-inflammatory activity.
  Vedolizumab (trade name Entyvio) is a monoclonal antibody developed by Millennium Pharmaceuticals, Inc (a subsidiary of Takeda Pharmaceuticals) for the treatment of ulcerative colitis and Crohn disease .
  See also
  integrin α4β7 (LPAM-1, lymphocyte Peyer’s patch adhesion molecule (...)

• denosumab
  18 May 2016

  trade names : Prolia and Xgeva WP
  Denosumab is a RANKL inhibitor, which works by preventing the development of osteoclasts which are cells that break down bone. It was developed by the biotechnology company Amgen.
  Denosumab is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone and giant cell tumor of bone .
  The most common side effects are joint and muscle pain in the arms or legs.
  Denosumab is contraindicated in people (...)

• ustekinumab
  10 May 2016

  WP
  Ustekinumab is directed against interleukin 12 (IL-12) and interleukin 23 (IL-23), naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.
  Ustekinumab (INN, experimental name CNTO 1275, proprietary commercial name Stelara, Centocor) is a human monoclonal antibody.
  It is manufactured in the Netherlands.
  It is directed against interleukin 12 and interleukin 23, naturally occurring proteins that regulate the immune system and (...)

• ixekizumab
  10 May 2016

  WP
  Ixekizumab binds to interleukin 17 and blocks its action. This mechanism is similar to that of another anti-psoriasis antibody, brodalumab, which also binds to the interleukin-17 receptor.
  See also
  IL-17 inhibitors

• brodalumab
  10 May 2016

  WP
  Brodalumab binds to the interleukin-17 receptor (IL17R) and so prevents interleukin 17 (IL-17) from activating the receptor. This mechanism is similar to that of another anti-psoriasis antibody, ixekizumab, which however binds to IL-17 itself.
  Brodalumab was developed by Amgen, Inc. In 2013, it was in two phase III clinical trials for the treatment of moderate to severe (...)

0 | 10 | 20 | 30 | 40